Investment group Medicxi said today it closed its $300 million Midicxi Growth 1 fund focused on growth stage companies in European life sciences. The fund is being backed by cornerstone strategic investors Novartis (NYSE:NVS), Verily and the European Investment Fund, and includes most of the institutional LPs that backed the firm’s 1st fund, as well as […]